Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (111-120 of 211) with videos related to

Pageof 22
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancerDavid R Spigel, John D Hainsworth, Jitendra G Gandhi, et al.
Clinical Lung Cancer|March 26, 2017
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage DiseaseMark A Socinski, Frederic J Kaye, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
Clinical Lung Cancer|October 10, 2007
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research NetworkF Anthony Greco, David R Spigel, Michel E Kuzur, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort studyThomas J Lynch, David R Spigel, Julie Brahmer, et al.
Cancer Discovery|December 8, 2021
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket StudyClaire F Friedman, John D Hainsworth, Razelle Kurzrock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerDavid R Spigel, Howard A Burris, F Anthony Greco, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLCDavid R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2015
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerDavid R Spigel, Jyoti D Patel, Craig H Reynolds, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2012
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, David M Waterhouse, et al.
Pageof 22

Showing results (111-120 of 211) with videos related to

Sort By:
Pageof 22
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancerDavid R Spigel, John D Hainsworth, Jitendra G Gandhi, et al.
Clinical Lung Cancer|March 26, 2017
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage DiseaseMark A Socinski, Frederic J Kaye, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
Clinical Lung Cancer|October 10, 2007
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research NetworkF Anthony Greco, David R Spigel, Michel E Kuzur, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort studyThomas J Lynch, David R Spigel, Julie Brahmer, et al.
Cancer Discovery|December 8, 2021
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket StudyClaire F Friedman, John D Hainsworth, Razelle Kurzrock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerDavid R Spigel, Howard A Burris, F Anthony Greco, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLCDavid R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2015
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerDavid R Spigel, Jyoti D Patel, Craig H Reynolds, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2012
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, David M Waterhouse, et al.
Pageof 22